| Active substance |
Letrozole |
| Also known as |
Letrozol |
| Blood pressure |
Can cause a decrease in blood pressure |
| Chemical name |
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile |
| Dosage (medical) |
2.5 mg daily |
| Dosage (sports) |
Typically 0.5 mg to 2.5 mg daily depending on purpose and cycling needs |
| Effects |
Reduces estrogen levels, increases luteinizing hormone and follicle-stimulating hormone levels |
| Formula |
C17H11N5 |
| Half-life |
2 days |
| Hepatotoxicity |
Low hepatotoxicity |
| Lab Test |
Monitoring of liver function tests, lipid profiles, and bone density |
| Main action |
Inhibits the enzyme aromatase, preventing the synthesis of estrogen |
| Side effects |
Hot flashes, joint pain, fatigue, increased risk of osteoporosis, nausea |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Substance class |
Aromatase inhibitor |
| Trade name |
Femara |
| Use in sports |
Used by bodybuilders and athletes to reduce estrogen levels and increase testosterone levels |
| Water Retention |
Reduces water retention |
| Active ingredient, mg |
2,5 |
| Release form |
Pills |
| 1 Pill, mg |
2,5 |
| Blister, pills |
2, 50 |
| Manufacturer |
Pharmacom Labs |
| Packing |
Packing (2 blisters), Blister (50 Pills) |
